Tag: law firm

SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- Girard Sharp LLP, a national investment, securities, and consumer class action firm, is investigating potential securities claims on behalf of former or current investors of 3M Company (“3M”) who received shares of Neogen Corporation (“Neogen” or the “Company”) in connection with Neogen’s acquisition of 3M’s Food Safety Business on September 1, 2022 (“Merger”).

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund (the “Easterly ROCMuni Fund”) (NYSE: RMJAX; RMHVK; RMHIX) shares between May 5, 2023 and June 12, 2025, inclusive (the “Class Period”), have until September 22, 2025 to seek appointment as lead plaintiff of the Easterly ROCMuni class action lawsuit. Captioned Victorson v. James Alpha Funds Trust d/b/a Easterly Funds Trust, No. 25-cv-06028 (S.D.N.Y.), the Easterly ROCMuni class action lawsuit charges the Easterly ROCMuni Fund, James Alpha Funds Trust d/b/a Easterly Funds Trust, investment adviser Easterly Investment Partners LLC and its former investment adviser Principal Street Partners, LLC, certain of the Easterly ROCMuni Fund’s underwriters, certain of their top executive officers and trustees, and others with violations of the Securities Exchange Act of 1933.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In BellRing Brands (BRBR) To Contact Him Directly To Discuss Their Options

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or “the Company”) (NYSE: ANRO) and certain of its officers.

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” Following this news, the price of the Company’s stock dropped. 

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).